Recon: Pfizer mulls over selling hospital drugs business; AstraZeneca plans $2B for US production, R&D boost

• Despite setback, AbbVie’s big bet on neuroscience has yet to play out (STAT)
• 23andMe cuts 40% of its workforce, discontinues all therapy programs (Reuters) (STAT)
• AstraZeneca budgets another $2B to boost manufacturing and R&D in US (Endpoints) (Reuters)
• US FDA declines full approval for Intercept's liver disease drug (Reuters)
• Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales (Reuters)
• Exclusive: Pfizer explores sale of hospital drugs unit, sources say (Reuters)
• Kennedy’s F.D.A. Wish List: Raw Milk, Stem Cells, Heavy Metals (NYTimes)

• Merck KGaA plans China submission after late-stage win for tumor drug (Endpoints)
• Bayer not eyeing new deals to address Xarelto sales erosion (Endpoints)
• EU Regulatory Round-Up: How Medtech Lobbying Altered EU Parliament’s Stance (MedTech Insight)
• Chinese Regulator Raises Red Flag On Clinical Trial Bribery (Pink Sheet)
• EMA's Final Call On Alzheimer's Drug Leqembi Imminent (Pink Sheet)
• New UK Rules On Supplementary Protection Certificates – Will You Be Affected? (Pink Sheet)
• EU Crunch Time For Kizfizo, Sipavibart, Coacillium & Eight Other Products (Pink Sheet)

• When even an ‘over the wall’ PIPE can’t help (STAT)
• Fueled by a ‘fall off your chair’ discovery and $101 million, Trace launches to take on ALS (STAT)
• Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor (Endpoints)
• Apollo makes a deal worth up to $926M; Abeona resubmits gene therapy (Endpoints)
• Neurogene's stock falls in post-market trading after early data in Rett syndrome (Endpoints)
• Alentis nabs $181M to broaden Claudin's scope in ADCs (Endpoints)
• Roche teams with Flare Therapeutics on transcription factors (Endpoints)
• Exclusive: GV-backed Medicaid startup Diverge Health raises $52M (Endpoints)
• Future Fields looks to solve industry's biomanufacturing woes with fruit fly-based protein production (Fierce Pharma)
• Cardinal Health expands gastroenterology, diabetes businesses with two deals worth $3.9 bln (Reuters)

• Invest in ‘triple rapid’ tests to fight mpox, H5N1 bird flu, and beyond (STAT)
• How Pfizer used wearables to tap into the promise of an experimental drug (STAT)
• Octave Bioscience’s Multi-Biomarker Test Provides Key Insights To Predict Multiple Sclerosis Disease State (MedTech Insight)
• J&J’s Ottava surgical robot to begin clinical trial after FDA nod (MedTech Dive)
• Boston Scientific resumes PFA trial in new patient group after pausing enrollment (MedTech Dive)
• GE Healthcare inks AI mammography pact with Radnet (MedTech Dive)

• The recovery community says it offers refuge from opioid addiction. But it’s still hostile to lifesaving addiction medications (STAT)
• OpenAI isn’t built for health care. So why is its tech already in hospitals, pharma, and cancer care? (STAT)
• US sues to block UnitedHealth's $3.3 bln purchase of Amedisys (Reuters)
• US epidemic of sexually transmitted infections shows signs of slowing, CDC says (Reuters)